Context: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET. Objective: To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting. Evidence acquisition: We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials. Evidence synthesis: We provide a comprehensive literature review on the current use of the PROMISE framework in clinical research and prospective trials. PROMISE variables demonstrate a clear association with survival. PSMA expression assessed by the PSMA-expression score was used in several trials, and a low PSMA-expression score is a negative prognosticator of overall survival after 177Lu-PSMA radioligand therapy. The proposed imaging parameters recorded for response assessment in clinical trials can be utilized to determine response according to PSMA-PET progression (PPP) or Response Evaluation Criteria in PSMA-PET/Computed Tomography (RECIP) frameworks, but also future response criteria. Conclusions: PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment. Patient summary: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2) / Seifert R.; Emmett L.; Rowe S.P.; Herrmann K.; Hadaschik B.; Calais J.; Giesel F.L.; Reiter R.; Maurer T.; Heck M.; Gafita A.; Morris M.J.; Fanti S.; Weber W.A.; Hope T.A.; Hofman M.S.; Fendler W.P.; Eiber M.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - ELETTRONICO. - 83:5(2023), pp. 405-412. [10.1016/j.eururo.2023.02.002]

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Heck M.;Fanti S.;
2023

Abstract

Context: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET. Objective: To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting. Evidence acquisition: We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials. Evidence synthesis: We provide a comprehensive literature review on the current use of the PROMISE framework in clinical research and prospective trials. PROMISE variables demonstrate a clear association with survival. PSMA expression assessed by the PSMA-expression score was used in several trials, and a low PSMA-expression score is a negative prognosticator of overall survival after 177Lu-PSMA radioligand therapy. The proposed imaging parameters recorded for response assessment in clinical trials can be utilized to determine response according to PSMA-PET progression (PPP) or Response Evaluation Criteria in PSMA-PET/Computed Tomography (RECIP) frameworks, but also future response criteria. Conclusions: PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment. Patient summary: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.
2023
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2) / Seifert R.; Emmett L.; Rowe S.P.; Herrmann K.; Hadaschik B.; Calais J.; Giesel F.L.; Reiter R.; Maurer T.; Heck M.; Gafita A.; Morris M.J.; Fanti S.; Weber W.A.; Hope T.A.; Hofman M.S.; Fendler W.P.; Eiber M.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - ELETTRONICO. - 83:5(2023), pp. 405-412. [10.1016/j.eururo.2023.02.002]
Seifert R.; Emmett L.; Rowe S.P.; Herrmann K.; Hadaschik B.; Calais J.; Giesel F.L.; Reiter R.; Maurer T.; Heck M.; Gafita A.; Morris M.J.; Fanti S.; Weber W.A.; Hope T.A.; Hofman M.S.; Fendler W.P.; Eiber M.
File in questo prodotto:
File Dimensione Formato  
Seifert_2023.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 808.37 kB
Formato Adobe PDF
808.37 kB Adobe PDF Visualizza/Apri
ScienceDirect_files.zip.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.62 MB
Formato Zip File
1.62 MB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/957729
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 42
  • ???jsp.display-item.citation.isi??? ND
social impact